Bleakley Financial Group LLC Purchases 13,177 Shares of Medtronic PLC $MDT

Bleakley Financial Group LLC increased its position in Medtronic PLC (NYSE:MDT) by 17.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,313 shares of the medical technology company’s stock after purchasing an additional 13,177 shares during the period. Bleakley Financial Group LLC’s holdings in Medtronic were worth $8,316,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of MDT. Intrust Bank NA lifted its stake in shares of Medtronic by 4.6% in the third quarter. Intrust Bank NA now owns 8,033 shares of the medical technology company’s stock valued at $765,000 after buying an additional 354 shares in the last quarter. EDENTREE ASSET MANAGEMENT Ltd increased its position in shares of Medtronic by 16.2% during the third quarter. EDENTREE ASSET MANAGEMENT Ltd now owns 246,741 shares of the medical technology company’s stock worth $23,492,000 after acquiring an additional 34,389 shares in the last quarter. Advyzon Investment Management LLC raised its holdings in shares of Medtronic by 22.1% in the 3rd quarter. Advyzon Investment Management LLC now owns 5,865 shares of the medical technology company’s stock worth $559,000 after acquiring an additional 1,060 shares during the last quarter. Personal CFO Solutions LLC lifted its position in Medtronic by 8.8% in the 3rd quarter. Personal CFO Solutions LLC now owns 10,737 shares of the medical technology company’s stock valued at $1,023,000 after acquiring an additional 870 shares in the last quarter. Finally, Raiffeisen Bank International AG boosted its stake in Medtronic by 18.7% during the 3rd quarter. Raiffeisen Bank International AG now owns 42,344 shares of the medical technology company’s stock valued at $3,979,000 after purchasing an additional 6,673 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Regulatory/coverage win in Japan for Medtronic’s Symplicity Spyral renal denervation device and management commentary that the company is investing in rollout and hiring to support market development — supports revenue upside from a growing hypertension therapy. Medtronic’s blood pressure device wins coverage nod in Japan
• Positive Sentiment: Analyst upgrade: Mizuho moved Medtronic to a “strong-buy,” which can support buying interest and short-term momentum. Mizuho upgrade reported via Zacks
• Neutral Sentiment: Industry growth tailwinds — a separate report highlights expansion in non‑invasive therapies (HIFU) and robotics/image‑guided systems; positive for device sector demand but not a direct Medtronic headline. HIFU Market Competitive Landscape Report 2025
• Neutral Sentiment: Competitive update — Intuitive Surgical (ISRG) reports faster international procedure growth, which underscores competitive dynamics in robotics and could pressure Medtronic’s robotics expectations over time. ISRG’s International Growth Outpaces US
• Neutral Sentiment: Company commentary and Q3 earnings materials are out (transcript available) showing mixed results: solid robotics wins but offset by some legal and expense items — provides context for guidance and valuation debate. Medtronic (MDT) Q3 2026 Earnings Call Transcript
• Negative Sentiment: Multiple broker notes lowered expectations or targets (JPMorgan, Robert W. Baird; Leerink cut its target to $119) — analyst downgrades/target cuts weigh on sentiment and can amplify selling. JPMorgan low expectations
• Negative Sentiment: Planned layoffs: Medtronic will cut 81 roles at a California diabetes site as it readies the diabetes spin‑out; restructuring adds near‑term execution risk and uncertainty around the separations. Medtronic to cut 81 employees at California diabetes site
• Negative Sentiment: Broader skepticism in media pieces discussing mixed quarterly results, legal exposure and whether recent wins materially change Medtronic’s investment case — fuels analyst disagreement and investor caution. Mixed Q3 Results, Robotics Win and Legal Hit

Medtronic Stock Down 0.7%

MDT opened at $96.88 on Friday. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company’s 50-day moving average price is $99.04 and its two-hundred day moving average price is $96.70. The stock has a market cap of $124.20 billion, a price-to-earnings ratio of 26.99, a PEG ratio of 2.43 and a beta of 0.71. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.88%. The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. During the same quarter in the previous year, the firm posted $1.38 EPS. Medtronic’s revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s payout ratio is currently 79.11%.

Analysts Set New Price Targets

Several analysts have recently commented on MDT shares. Jefferies Financial Group reissued a “hold” rating and issued a $110.00 price objective on shares of Medtronic in a research note on Wednesday, November 19th. JPMorgan Chase & Co. lowered their price target on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday. UBS Group restated a “neutral” rating and set a $104.00 price objective on shares of Medtronic in a research note on Wednesday, February 4th. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the company a “neutral” rating in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $110.84.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).